A single injection of a Gene-Editing treatment was found to have a lower cholesterol

British drugmaker Verve has claimed it’s made the world’s first gene-editing drug which could lower cholesterol. The drug alters adenine bases in the body and another that recognises PCSK9. It swaps a base with a guanine base to turn off PCSK9, preventing liver cells from producing PCSK9 proteins. Verve aims to select the best therapeutic dose from the trial next year.